Photodynamic Therapy With Verteporfin for Corneal Neovascularization - Full Text View

Sponsored by:	Chonnam National University Hospital
Information provided by:	Chonnam National University Hospital
ClinicalTrials.gov Identifier:	NCT00471406

Purpose

Purpose: To investigate the efficacy of photodynamic therapy with verteporfin for the treatment of patients with corneal neovascularization.

Design: Prospective, non-comparative case series. Participants: Eighteen eyes of 18 patients with stable corneal neovascularization who were refractory to conventional treatment.

Methods: The patients were treated with photodynamic therapy with verteporfin (6 mg/m2). Five patients were treated following penetrating keratoplasty, and 2 patients were treated before penetrating keratoplasty. Best corrected visual acuity and anterior segment photography were performed before and after treatment. The length of cumulative blood vessels and area of corneal neovascularization were measured.

Main outcome measures: Vascular occlusion, best corrected visual acuity, cumulative blood vessel length, and corneal neovascularization area.

Condition	Intervention
Corneal Neovascularization	Procedure: Photodynamic Therapy with Verteporfin

Drug Information available for: Verteporfin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment

Eligibility

Ages Eligible for Study:	35 Years to 70 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Patients with clinically stable corneal neovascularization who were not improved after treatment with 1% prednisolone acetate eyedrops instilled 4 times a day for at least 1 month

Exclusion Criteria:

Individuals who had active keratitis with vessel proliferation, uncontrolled inflammation, active hepatitis or clinically significant liver disease, or porphyria or other porphyrin sensitivity

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00471406

Sponsors and Collaborators

Chonnam National University Hospital

Investigators

Study Director:

Kyung chul Yoon, MD

Chonnam natianl university hospital

More Information

Study ID Numbers:	CPDT-0001
Study First Received:	May 8, 2007
Last Updated:	October 16, 2008
ClinicalTrials.gov Identifier:	NCT00471406
Health Authority:	Korea: Food and Drug Administration

Study placed in the following topic categories:

Corneal Diseases
Eye Diseases
Metaplasia

Verteporfin
Neovascularization, Pathologic
Corneal Neovascularization

Additional relevant MeSH terms:

Photosensitizing Agents
Pathologic Processes
Radiation-Sensitizing Agents
Therapeutic Uses

Physiological Effects of Drugs
Dermatologic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009